

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on April 16, 2007.

Frank C Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121
Examining Group 1617
Patent Application
Docket No. UF-389
Serial No. 10/700,156

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Jennifer M. Kim
Art Unit : 1617
Applicants : Nathan Andrew Shapira, Giselle D. Mann, April M. Annis, Toby Doris Goldsmith
Serial No. : 10/700,156
Filed : November 3, 2003
Conf. No. : 3799
For : Methods to Prevent or Ameliorate Medication-, Procedure- or Stress-Induced Cognitive and Speech Dysfunction and Methods to Optimize Cognitive and Speech Functioning

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

ELECTION UNDER 35 U.S.C. § 121

Sir:

In response to the written Restriction Requirement dated March 16, 2007 in the above-identified patent application, Applicants hereby elect, for purposes of examination in the subject application, the species of atomoxetine.